Navigation Links
CV risk management should be mandatory in RA and other types of inflammatory rheumatic disease
Date:6/13/2008

Paris, France, Friday 13 June 2008: Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients should undergo compulsory cardiovascular (CV) risk management and existing CV risk calculators should be adapted to the increased CV risk in inflammatory rheumatic disease patients, the EULAR Task Force on 'Cardiovascular Risk Management in RA' recommended today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.

RA, AS and PsA are associated with an increased CV risk and, in RA, this risk is at least double the norm and potentially similar to that of type 2 diabetes, a clinically-established cardiovascular risk factor. The EULAR Task Force set out to review existing evidence and expert opinion-based recommendations on CV management in inflammatory rheumatic disease, in order to devise specific EULAR recommendations for future clinical practice.

The EULAR Task Force's multidisciplinary steering committee comprised 21 members, including rheumatologists, cardiologists, internists and epidemiologists, from across nine European countries (France, Germany, Greece, Hungary, Norway, Portugal, Spain, The Netherlands, United Kingdom). Their recommendations were as follows:

  1. RA, AS and PsA should become clinically accepted as new CV risk factors.

  2. Existing CV-risk calculators, such as the Framingham and Systematic Coronary Risk Evaluation (SCORE), should be adapted, by a multiplier, to reflect the increased CV risk in inflammatory rheumatic disease patients.

  3. Annual cardiovascular risk screening is recommended for all RA patients and should be considered for AS and PsA patients.

  4. Lifestyle recommendations (on areas including diet, exercise, smoking cessation and stress management) should be given to all inflammatory rheumatic disease patients.

  5. Treatment with statins and/or antihypertensives should be considered, and the CV management targets should be set according to local guidelines. If there are no local guidelines, treatment should be considered when the 10 year CV mortality risk with the (newly adapted) Framingham/SCORE function is above a certain value.

  6. Aggressive inflammation suppression is recommended to further lower the CV risk in patients with inflammatory rheumatic disease.

Dr Michael Nurmohamed, lead investigator and convenor of this EULAR Task Force said, "Although traditional cardiovascular risk factors occur more frequently in patients with inflammatory rheumatic disease than in the general population, they only partially explain these patients' increased cardiovascular risk. There is mounting evidence that inflammation may be the missing link. Therefore, disease modifying antirheumatic drugs (DMARD) and biologics may lower the cardiovascular risk in inflammatory rheumatic disease patients, whilst statins and hypertensives, such as ACE inhibitors and angiotensin blockers, may even yield greater benefits than in the general population due to their anti-inflammatory properties."

Professor Ferdinand Breedveld, President of EULAR said, "These recommendations have been developed in accordance with the EULAR Standardised Operating Procedures and in line with the EULAR objectives to improve the understanding of musculoskeletal disorders and contribute to the improvement of outcome of patients with rheumatic disorders. The Task Force is to be commended on its excellent recommendations which will directly contribute to improved clinical practice and better understanding of the management of CV factors in rheumatology."

CV risk factor stratification and management is currently conducted on the basis of 10 years absolute risk for a (fatal) CV-event, as derived from a risk formula based on a number of CV-risk factors. The two major standard CV risk calculators are Framingham, a tool based on US population statistics and SCORE, tailored to European populations.


'/>"/>

Contact: Rory Berrie / Camilla Dormer
eularpressoffice@uk.cohnwolfe.com
44-077-892-70392
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Birner Dental Management Services, Inc. Declares $.17 Quarterly Dividend
2. Rising Medical Solutions Chooses Bank of America to Bring Enhanced Cash Management and Provider Payment Solutions to the Marketplace
3. Cancer Clinics of Excellence (CCE) Announces Management and Board of Directors Slate at 1st Annual General Membership Meeting
4. Benchmarking Study Report on Sales Performance Management
5. New self-management program offers significant benefits for arthritis patients with chronic pain
6. Edge Health Solutions Releases edgeDMS(TM) 2.0 and edgeMD 2.0(TM), Revolutionary All-in-One Practice Management Software with FDA-Approved Advanced Visualization
7. Medical Mutual of Ohio Receives URAC Utilization Management Accreditation
8. Rush-Copley Medical Center Selects Allscripts Electronic Health Record and Practice Management Solution
9. Weight Management Solution Helps You Lose or Gain as Much Weight as You Choose
10. Aribex(R) Continues Growth With New Management, Organization
11. ECRI Institutes Alert and Recall Management System Expands Effectiveness with New Content and Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... "I have ... "I used this old family recipe, which is meant to relieve gout and pain ... gave me a 12-hour energy boost every time. It relieved what VA doctors called ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
(Date:12/9/2016)... Smithsburg, Maryland (PRWEB) , ... December 09, 2016 ... ... intelligent digital whiteboard display solutions, proudly announced today that a new solution for ... package to fit in the tight space in Emergency Department examination rooms, and ...
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... LLC, announced the first national #QuackGivesBack campaign which supported local breast cancer ... our first franchise-wide Quack Gives Back initiative, and we’re very pleased ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/9/2016)... 9, 2016  Forge Therapeutics, Inc. today announced ... Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance its ... treatment of bacterial infections including those caused by ... an attractive antibacterial target for more than the ... chemical starting points has hampered its progress. Forge ...
(Date:12/8/2016)... 8, 2016 Australia Ophthalmic Lasers Market Outlook ... Ophthalmic Lasers Market Outlook to 2022", provides key market ... provides value, in millions of US dollars, volume (in ... Excimer Lasers, Femtosecond Lasers and YAG Lasers. The ... for each of these market segements, and global corporate-level ...
Breaking Medicine Technology: